Europe Methadone Market

Europe Methadone Market Size

The Europe methadone market is projected to grow from USD 40.30 million in 2024 to USD 56.82 million by 2033, at a CAGR of 3.89% from 2024 to 2033.

MARKET OVERVIEW

The European methadone market is primarily driven by the increasing prevalence of pain associated with therapeutic and post-surgical treatment, increasing the demand for the drug. Furthermore, chronic pain and the high prevalence of chronic diseases are more common among adults living in poverty. In addition, the growth and launch of new methadone-containing products by key companies are driving the market growth during the forecast period.

The incidence of high-risk opioid use among adults (15-64 years) in Europe has been relatively stable for several years, with use estimates of around 0.358% of the European Union. WHO guidelines for opioid drug therapy with psychosocial support recommend that for most clients, opioid substitution therapy with methadone is used in preference to detoxification, that methadone is used in choice to buprenorphine for drug addiction services, including in prisons. This factor will positively support the market growth in the years to come.

Additionally, in response to the reduction of inaccessibility to COVID-19 treatment services during the lockdown, some countries have increased opioid replacement drugs, for example, by allowing pharmacies to distribute methadone, as seen in the United Kingdom. To increase accessibility to opioid substitution treatment, the UK plans to use methadone without new prescriptions to existing users. Methadone is often detected alongside opioids in overdose deaths in Europe, the predominant stimulant. Additionally, the role methadone plays in cardiovascular disease-related complications may increase sales.

However, misuse of methadone, such as overdosing or stopping the dose without the doctor's consent, can lead to increased heart rate, hallucinations, and shortness of breath. Therefore, it can also hamper the growth of the market.

In addition, some factors may challenge the growth of the European market in the coming years. For example, specific risks associated with the use of methadone in patients with severe asthma or breathing problems, a mix-up with other CNS depression drugs may restrict its use, which could slow down the market for methadone. In addition, stringent rules and the legalization of methadone will slow the market.

COUNTRY LEVEL ANALYSIS

The UK methadone market is anticipated to dominate the European methadone market during the given period. The growth of this regional market is attributed to the increasing prevalence of cancer and the growing need for methadone as maintenance therapy treatment and detoxification. In addition to this, leading suppliers operating in the region are also a key growth factor.

Furthermore, since 2014, the number of persons seeking treatment for illicit drug problems has been increasing; although still relatively small, the use of methadone has risen by more than 35.6%. Therefore, it is predicted to give new growth opportunities helping the market in the coming years.

On the other hand, the Germany methadone market is expected to experience a favorable growth rate of 3.5% in the next few years of the forecast period from 2023 to 2028. The market is driven by increased drug abuse and growing demand for severe pain-relieving options.

KEY MARKET PLAYERS

Key players operating in the European Methadone Market profiled in this report are Diskets, Methadoes, Aurolife Pharma LLC, Macfarlan Smith, VistaPharm, Qinghai Pharm, CentralPharm, Mallinckrodt, and Roxane (Boehringer Ingelheim) among others.

MARKET SEGMENTATION

This research report on the Europe Methadone Market has been segmented and sub-segmented into the following categories:

By Application

• Operation
• Detoxification
• Others

By Mode Of Administration

• Injections
• Oral Medicine

By Country

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe